Medivir has presented Lipsovir® at the ongoing 49th ICAAC meeting in San Francisco, USA

Medivir presented Lipsovir® (ME-609) at a poster session on 14th September at the ongoing ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) meeting. The conclusions highlighted in the presentation: ME-609 prevented ulcerated lesions in subjects with recurrent HSL compared to both topical acyclovir and placebo. In subjects who developed an ulcerative lesion despite treatment, the healing time was reduced by ME-609 with 1.6 days as compared to placebo. The cumulative lesion area, a global endpoint that also incorporates the preventive effect on ulcerative lesions, was reduced by half in the ME-609 group compared to placebo and was significantly smaller than in both the acyclovir and placebo groups. ME-609 was approved for marketing in United States on July 31, 2009 with the following indication: “ME-609 is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time”. The poster is available to access on our website under IR & Media/latest events/ICAAC

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).


Documents & Links